ATAI Life Sciences N.V.

News & Events

Press Releases

In The Media

1. atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

   GlobeNewswire MAR 17, 2025 8:00 AM EDT
   - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients w...
   READ ARTICLE

2. atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

   GlobeNewswire MAR 11, 2025 7:00 AM EDT
   - Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial...
   READ ARTICLE

3. atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

   GlobeNewswire MAR 5, 2025 7:00 AM EST
   - The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is ev...
   READ ARTICLE

4. atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

   GlobeNewswire FEB 24, 2025 4:10 PM EST
   NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (&#x...
   READ ARTICLE

5. atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

   GlobeNewswire FEB 20, 2025 7:00 AM EST
   NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Lif e Sciences (NASDAQ: ATAI) (&#...
   READ ARTICLE

6. atai Life Sciences Announces Pricing of Public Offering of Common Shares

   GlobeNewswire FEB 12, 2025 10:47 PM EST
   NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) ...
   READ ARTICLE

7. atai Life Sciences Announces Proposed Public Offering of Common Shares

   GlobeNewswire FEB 12, 2025 4:01 PM EST
   NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (&#x...
   READ ARTICLE

8. atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder

   GlobeNewswire JAN 28, 2025 7:00 AM EST
   - A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sus...
   READ ARTICLE

9. atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health

   GlobeNewswire JAN 10, 2025 7:00 AM EST
   - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D....
   READ ARTICLE

10. atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

    GlobeNewswire NOV 13, 2024 8:00 AM EST
    - The United States Food and Drug Administration cleared the investigational new drug application...
    READ ARTICLE